Compare Summit Therapeutics Inc (SMMT) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Upstart Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $17.44 (market cap $13.71B), while Upstart Holdings Inc trades at $24.24 (market cap $2.35B). The key difference: Summit Therapeutics Inc is far larger — about 5.8× Upstart Holdings Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Upstart Holdings Inc for 39 Days on average.
| SMMT | UPST | |
|---|---|---|
Market Cap | $13.71B | $2.35B |
Volume | 6,173,057 | 4,203,337 |
Sector | Health | Financials |
52-Week High | $26.38 | $52.74 |
52-Week Low | $12.43 | $22.81 |
Typical Hold Time | 16 Days | 39 Days |
Enterprise Value | $13.04B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Upstart Holdings trades at $24.24, up 0.9% with a bearish technical signal despite recent earnings misses. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though cash flow from operations remains negative at -$147.7M. Recent news highlights partnership expansions into HELOC and auto lending while the stock faces pressure from broader consumer lending sector weakness.
Upstart's AI lending platform shows revenue growth potential but faces execution risks amid volatile credit markets. Analyst consensus targets $39.50 (63% upside) with mixed ratings, while high P/E of 46.5 suggests premium valuation. The key risk remains the company's loan syndication model during economic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
